PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
IPO Year: 2018
Exchange: NASDAQ
Website: phasebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2022 | $15.00 → $1.00 | Buy → Hold | Stifel |
| 10/13/2021 | $15.00 | Buy | Stifel |
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer. "Jonathan brings to PhaseBio deep commercial expertise in the critical-care setting, which he gained through his leadership of the thrombolytics franchise at Genentech," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "With his background and track record of success, Jonathan has the experience necessary to lead our commercial organization and joins us at a pivotal time in PhaseBio's evolution as we begin prepar
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its board of directors. Additionally, Justin Klein, M.D., J.D., is stepping down from his role as director, effective immediately. "Bill's deep commercial expertise gained through his leadership roles at numerous specialty pharmaceutical companies will be an invaluable addition to our already robust board of directors," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "Bill joins us at an exciting and pivotal time in PhaseBio's growth, as
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
NT 10-Q - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
NT 10-Q - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
NT 10-Q - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
8-K - PhaseBio Pharmaceuticals Inc (0001169245) (Filer)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13D/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
SC 13G/A - PhaseBio Pharmaceuticals Inc (0001169245) (Subject)
PhaseBio recently received formal written minutes from the FDA following its Pre-BLA Meeting held in early April and is expecting to submit its Biologics License Application (BLA) by early in the fourth quarter of 2022 The FDA indicated willingness to accept a BLA with data from 25-30 uncontrolled bleeding patients, in addition to surgical patients enrolled to date, to potentially support a label that includes both surgical and uncontrolled bleeding indications To date, PhaseBio has enrolled 35 uncontrolled bleeding patients and has completed enrolling surgical patients in the Phase 3 REVERSE-IT trial Conference call and webcast today at 8:30 a.m. ET PhaseBio Pharmaceuticals, Inc. (NASD
Global Phase 3 trial of bentracimab achieved primary reversal endpoint with immediate and sustained reversal of the antiplatelet effects of ticagrelor in both surgical and bleeding populations Co-primary endpoint of clinical hemostasis achieved in greater than 90% of patients Bentracimab appeared well tolerated with no drug-related serious adverse events Results presented today in Late-Breaking Science Session at the American Heart Association's 2021 Scientific Sessions and accepted for publication in NEJM Evidence, a new digital journal from the NEJM (New England Journal of Medicine) Group Investor webcast scheduled for today at 12:30 p.m. ET PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHA
Prespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November 15th at the American Heart Association's Scientific Sessions 2021 Guest speakers include Deepak L. Bhatt, M.D., MPH; Charles Pollack, M.D.; and Philippe Gabriel Steg, M.D. Video webcast to be held on November 15, 2021, at 12:30 p.m. ET (9:30 a.m. PT) PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host an investor call on November 15, 2021, at 12:30 p.m. ET (9:30 a.m. PT) to discuss the results
Stifel downgraded PhaseBio Pharmaceuticals from Buy to Hold and set a new price target of $1.00 from $15.00 previously
Stifel resumed coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00
Needham reiterated coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $15.00 from $16.00 previously
Needham reiterated coverage of PhaseBio Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $18.00 previously
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4/A - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
4 - PhaseBio Pharmaceuticals Inc (0001169245) (Issuer)
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. As part of the case, PhaseBio also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities. "The second quarter of 2022 marked a period of continued progress for PhaseBio," said Jonathan Mow, Chief Executive Officer of PhaseBio Pharmaceuticals. "Following a successful meeting with the U.S. Food and Drug Administration (FDA) during our pre-biologics license application (pre-BLA) meeting earlier this year and as previously disclosed, we have been focused on clinical developmen
Held successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commercialization in U.S., if approved Presented positive results from Phase 2b trial for bentracimab at ACC.22 Completed the Process Performance Qualification (PPQ) campaign demonstrating commercial scale manufacturing ability for bentracimab PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financia
PhaseBio recently received formal written minutes from the FDA following its Pre-BLA Meeting held in early April and is expecting to submit its Biologics License Application (BLA) by early in the fourth quarter of 2022 The FDA indicated willingness to accept a BLA with data from 25-30 uncontrolled bleeding patients, in addition to surgical patients enrolled to date, to potentially support a label that includes both surgical and uncontrolled bleeding indications To date, PhaseBio has enrolled 35 uncontrolled bleeding patients and has completed enrolling surgical patients in the Phase 3 REVERSE-IT trial Conference call and webcast today at 8:30 a.m. ET PhaseBio Pharmaceuticals, Inc. (NASD
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference taking place virtually on Thursday, April 14, 2022 from 1:30 – 2:10 pm ET. Interested parties can access the live and archived webcasts of the virtual session on the "Events and Presentations" page of the "Investors" section of the company's website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation. Abo
Results presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology's 71st Annual Scientific Session (ACC.22) Trial achieved primary reversal endpoint in older volunteers Bentracimab was well tolerated in the Phase 2b trial, with no drug-related serious adverse events or thrombotic events reported PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced the complete results from its Phase 2b clinical trial of bentracimab that were presented on April 2nd during a Late Breaking Featur
Achieved key clinical milestones for bentracimab program, with positive results from both the completed Phase 2b trial and interim analysis of the ongoing REVERSE-IT global Phase 3 trial Company remains on track to submit Biologics License Application (BLA) for bentracimab in mid-2022 and is preparing for expected commercialization in U.S. PB6440, the company's aldosterone synthase inhibitor in development for resistant hypertension, on track for submission of an Investigational New Drug application (IND) in the second half of 2022 PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies f
Manufacturing of bentracimab drug substance and drug product Process Performance Qualification (PPQ) batches has been completed PhaseBio remains on track to submit bentracimab Biologics License Application (BLA) in mid-2022 PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the completion of the bentracimab drug substance and drug product Process Performance Qualification (PPQ) campaign. The PPQ campaign consisted of multiple commercial scale runs required for the validation of the bentracimab manufacturing process and the demonstration of
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen's 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET. Interested parties can access the live and archived webcasts of the virtual session on the "Events and Presentations" page of the "Investors" section of the company's website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live present
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Phase 2b trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old, has been accepted for presentation in a Late Breaking Clinical Research session at the American College of Cardiology Annual Scientific Session & Expo being held in Washington, D.C., April 2-4, 2022. The Phase 2b trial is a multi-center, randomized, double-blind, placebo-controlled study with 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated w